STERIS Continues To Expect As Reported Revenue From Continuing Operations To Increase 6.5-7.5% In Fiscal 2025; Adjusted EPS To Be In The Range Of $9.05-$9.25 Vs $9.14 Est.
STERIS Continues To Expect As Reported Revenue From Continuing Operations To Increase 6.5-7.5% In Fiscal 2025; Adjusted EPS To Be In The Range Of $9.05-$9.25 Vs $9.14 Est.
Fiscal 2025 Outlook Reiterated
For fiscal 2025, the Company continues to expect as reported revenue from continuing operations to increase 6.5-7.5%. Based on forward rates through March 31, 2025, currency is expected to be neutral to revenue in fiscal 2025. Constant currency organic revenue from continuing operations is anticipated to increase 6-7%. In April 2024, the Company completed a divestiture of its Controlled Environment Services business within the Life Sciences segment. Total annual revenue for this business in fiscal 2024 was approximately $35 million which will be excluded from constant currency organic revenue growth from continuing operations in fiscal 2025. Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25 compared with $8.20 in adjusted earnings from continuing operations in fiscal 2024. The fiscal 2025 outlook assumes an effective tax rate of approximately 23%. Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.
2025財年展望重申
對於2025財年，公司預計持續營運業務的報告營業收入將增長6.5-7.5%。根據2025年3月31日的遠期匯率，預計貨幣在2025財年對營業收入不產生影響。持續營運業務的不變匯率有機營業收入預計將增加6-7%。2024年4月，公司完成了在生命科學領域內受控環境服務業務的剝離。該業務在2024財年的總收入約爲3500萬美元，將在2025財年的不變匯率有機營業收入中被排除在外。持續營運業務的每股攤薄調整收益預計爲$9.05至$9.25，相比於2024財年持續營運業務的調整收益$8.20。2025財年展望假設有效稅率約爲23%。預計資本支出將約爲36000萬美元，自由現金流預計約爲70000萬美元。
